Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Isolyser (OREX)- Any comments -- Ignore unavailable to you. Want to Upgrade?

To: Steve who wrote (571)	4/29/1998 6:37:00 PM
From: Zencone	Read Replies (2) \| Respond to of 617

I recently e-mailed Isolyser and received the following response: We appreciate your interest in Isolyser and thank you for your support. We are diligently working towards what we believe will be a successful turnaround in time. After analysis by Goldman Sachs and Morgan Keegan, our Board determined that we must redirect our focus and significantly reduce our debt, thus,on March 3, 1998 we announced our 2nd restructuring since the turnaround began 11 months ago. Part of the plan includes selling our base material manufacturing facilities which have not been operating at 100% capacity for some time now. We are also selling our White Knight Healthcare division in Arden. Simultaneously, we are forming three semi-autonomous business units: OREX commercialization; ICG (Infection Control Group); and Product Packaging. ICG will be based out of Columbus, MS. This restructuring will leave us with profitable strategic business units that have strong market positions and that, we feel, can help Isolyser achieve profitability. Additionally, our ICG division will provide the structure for contact within the healthcare market in order to promote, support, and provide input for the further development of our OREX technology. We believe the OREX technology will have increasing value as environmental issues become increasingly important in a broad range of markets. Thank you again for your interest and your patience in awaiting a response from me. SUSAN TANNER